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Abstract
Objective: The human immunodeficiency virus (HIV) is one of the fastest
evolving organisms in the planet. Its remarkable variation capability makes
HIV able to escape from multiple evolutionary forces naturally or artificially
acting on it, through the development and selection of adaptive mutations.
Although most drug resistance mutations have been well identified, the dy-
namics and temporal patterns of appearance of these mutations can still
be further explored. The use of models to predict mutational pathways as
well as temporal patterns of appearance of adaptive mutations could greatly
benefit clinical management of individuals under antiretroviral therapy.
Methods and Material: We apply a temporal nodes Bayesian network (TNBN)
model to data extracted from the Stanford HIV drug resistance database in
order to explore the probabilistic relationships between drug resistance mu-
tations and antiretroviral drugs unveiling possible mutational pathways and
establishing their probabilistic-temporal sequence of appearance.
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Results: In a first experiment, we compared the TNBN approach with other
models such as static Bayesian networks, dynamic Bayesian networks and
association rules. In a second experiment, the TNBN model was applied to
a dataset associating antiretroviral drugs with mutations developed under
different antiretroviral regimes. The learned models captured previously de-
scribed mutational pathways and associations between antiretroviral drugs
and drug resistance mutations.
Conclusion: our results suggest possible applications of TNBN for studying
drug-mutation and mutation-mutation networks in the context of antiretro-
viral therapy, with direct impact on the clinical management of patients
under antiretroviral therapy. This opens new horizons for predicting HIV
mutational pathways in immune selection with relevance for vaccine design.
Keywords: Temporal nodes Bayesian networks, learning Bayesian
networks, human inmundeficency virus mutations
1. Introduction
Viral evolution is an important aspect of the epidemiology of viral dis-
eases such as influenza, hepatitis and the acquired immunodeficiency syn-
drome (AIDS). This evolution greatly impacts the development of successful
vaccines and antiviral drugs, as mutations conferring immune escape or drug
resistance often develop early after the virus is placed under selective pres-
sure. This is particularly relevant for human immunodeficiency virus (HIV),
a virus ranking among the fastest evolving organisms in the planet [1]. The
remarkable viral replication capability of HIV is coupled with a high muta-
tion rate and a high probability of recombination in the viral genome during
its replication cycle. These features allow HIV to boast a wide genetic vari-
ability even considering only the viral population within a given host. This
variation capability gives the virus a remarkable ability to adapt to multiple
selective pressures, including the immune response and antiretroviral therapy.
Several questions remain open regarding HIV intra-host genetic variability,
for example: To what extent do selective pressures such as immune responses
and antiretroviral treatment shape viral evolution compared to genetic drift?
What is the relationship between genetic diversity and clinical outcome? Is
it feasible to anticipate HIV evolution in order to reduce drug resistance and
viral adaptation to immune responses? In the case of this last question, be-
ing able to predict mutational pathways in HIV and their timely patterns of
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appearance could help to anticipate viral adaptation and plan timely inter-
ventions with the proper monitoring of infected individuals. In the present
study, we addressed the problem of finding mutation-mutation and drug-
mutation associations in individuals receiving antiretroviral therapy, using
temporal nodes Bayesian networks (TNBN). We have focused on protease
inhibitors (PIs), a family of antiretroviral drugs widely used in modern an-
tiretroviral therapy. PIs block the activity of the viral protease, an enzyme
that processes viral precursor polyproteins in order to promote viral matu-
ration and infectivity. It is well described that resistance to PIs results from
the accumulation of mutations that together modify the conformation of the
enzyme.
Our goal was to test whether the model could predict previously de-
scribed mutational pathways for specific drugs. Our probabilistic graphical
model correctly identified antiretroviral drug-associated mutational patterns
in the protease gene, revealing the co-occurrence of mutations and its tem-
poral relationships. This work1 is organized as follows. Section 2 highlights
some basic notions regarding HIV and how it develops drug resistance. Sec-
tion 3 justifies the use of TNBN over other existing graphical probabilistic
approaches. Section 4 describes the TNBN model. Section 5 presents the
first experiments and compares TNBN with other three approaches. Section
6 presents the results of a learned TNBN with specific drugs and important
mutations; this section highlights the clinical relevance of the results. Finally,
Section 7 summarizes the findings and indicates future lines of research.
2. HIV and its defense against antiretroviral therapy
2.1. Motivation
HIV is the causing agent of AIDS, a condition in which progressive failure
of the immune system allows opportunistic life-threatening infections to oc-
cur. HIV is a virus with relatively recent introduction to human populations
[2] representing a huge global burden to human health [3].
The HIV replication cycle is characterized by a reverse-transcription step
of the viral RNA genome to a double-stranded DNA molecule, which is then
1This paper is an expanded version of “Unveiling HIV mutational networks associated
to pharmacological selective pressure: a temporal Bayesian approach” presented in: A.
Hommersom and P. Lucas, editors. Probabilistic Problem Solving in Biomedicine Work-
shop (ProBioMed-11), Bled Slovenia.
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inserted into the host cell genome. To combat HIV infection several antiretro-
viral (ARV) drugs belonging to different drug classes that affect specific steps
in the viral replication cycle have been developed. Antiretroviral therapy
(ART) generally consists of well-defined combinations of three or four ARV
drugs. Due to its remarkable variation capabilities, HIV can rapidly adapt
to the selective pressure imposed by ART through the development of drug
resistance mutations, that are fixed in the viral population within the host in
known mutational pathways. The development of drug resistant viruses com-
promises HIV control, with a consequent further deterioration of the patient’s
immune system. Hence, there is interest in having a profound understanding
of the dynamics of appearance of drug resistance mutations. We focus our
analyses on one of the most common target proteins of antiretroviral drugs:
the viral protease, an enzyme that cleaves viral polyprotein precursors into
mature proteins. The protease acts late in HIV replication cycle and is es-
sential for viral infectivity. Drugs designed to interfere with protease are
known as protease inhibitors. Resistance to PIs occurs via the accumulation
of primary and secondary mutations that are located within and outside of
the enzyme active site, respectively [4]. The patterns of mutations selected
by currently available PIs have been characterized [5, 6]. More than 20% of
the 99 amino acids comprising the HIV protease have been shown to mutate
in response to drug pressure. Consequently, the genotypic patterns in pa-
tients with PI-resistant HIV are complex. The primary mutations selected
by different PIs may be drug-specific, but secondary mutations tend to be
common to several drugs in the PI class, potentially limiting the success of
subsequent PI therapy following failure on any PI-containing regimen [7].
Moreover, the appearance of some drug resistance mutations implies high
costs for viral replication capacity. These costs in viral replication capacity
are often compensated by the appearance of additional mutations known as
compensatory mutations. Due to their polymorphic nature the frequency
of compensatory mutations can vary between viruses circulating in different
geographic areas, making it relevant to study HIV mutational pathways in
the context of different infected populations.
2.2. Related work
Abundant literature exists describing computational models aimed to bet-
ter understand HIV evolution and immunopathogenesis. A good part of these
models is devoted to predicting phenotypic HIV resistance to antiretroviral
drugs using different approaches such as decision trees [8] or neural networks
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[9]. Other models have tried to identify relevant associations between clinical
variables and HIV disease [10]. Surprisingly, among this wealth of literature,
works aimed towards the identification of temporal relationships among mu-
tations and drugs in HIV are scarce.
In [11] association rules between clinical variables and ART failure were
assessed. The authors used 15 clinical variables from 8000 patients from data
collected since 1981. The results obtained were temporal rules that have as
antecedent the increase of a subset of clinical variables and as consequent
ART failure. None of the clinical variables considered were HIV mutations.
Some other works using probabilistic models have studied the development
of resistance to PIs, mainly Nelfinavir, Indinavir and Saquinavir, through
learned Baysian networks [12, 13]. However, none of these learned models
yielded any temporal information.
Finally, in [14], the order of appearance of resistance mutations in re-
verse transcriptase was assessed. In order to overcome the scarce amount of
longitudinal data available for patients under the same antiretroviral regi-
men, the authors used large sets of cross-sectional data. By using a variant
of the expectation-maximization algorithm they learned a mixture model of
directed trees that accurately captured the order in which mutations of the
HIV-1 reverse transcriptase accumulate.
In this work, we proposed a novel approach to study antiretroviral drug
resistance mutation dependencies and temporal relations. We use temporal
nodes Bayesian networks because of their capacity to obtain a global repre-
sentation of the temporal dynamics of HIV mutations.
3. Bayesian networks
Information in clinical databases is often imprecise, incomplete, and with
errors (noisy). Bayesian Networks (BNs) [15] are probabilistic graphical mod-
els particularly well suited to deal with uncertainty. BNs represent probabilis-
tic dependencies among domain entities. BNs have a visual representation,
a graph consisting of nodes and edges facilitating their analysis and inter-
pretation. Nodes represent random variables and edges represent a set of
conditional independence assumptions [16]. This kind of graphical represen-
tation can be easily understood. An additional advantage is the availability
of several methods to learn BNs from data [17].
BNs have proven to be successful in various domains such as medicine
[18, 19] and bioinformatics [20–23]. However, classical BNs are not well
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equipped to deal with temporal information. dynamic Bayesian networks
(DBNs) evolved to tackle this shortcoming [24]. DBNs can be seen as multi-
ple slices of a static BN over time, with temporal relations captured as links
between adjacent slices. In a DBN, a base model is cloned for each time
stage. These copies are linked via the so-called transition network. In this
transition network is common that only links between consecutive stages are
allowed. Whenever temporal changes occur infrequently, the DBN represen-
tation becomes unnecessarily over expressive. One alternative are temporal
nodes Bayesian networks [25].
4. Temporal nodes Bayesian networks
In a TNBN, each node, known as temporal node (TN), represents a ran-
dom variable that may be in a given state i.e. value interval, throughout the
different temporal intervals associated to it. An arc between two temporal
nodes describes a temporal-probabilistic relation. In TNBNs, each variable
(node) represents an event or state change. So, only one (or a few) instance(s)
of each variable is (are) required, assuming there is one (or a few) change(s) of
a variable state in the temporal range of interest. No copies of the model are
needed, thus compacting the representation without losing expressiveness.
A TNBN [25, 26] is composed by a set of TNs connected by arcs rep-
resenting a probabilistic relationship between TNs. A TN, vi, is a random
variable characterized by a set of states S. Each state is defined by an ordered
pair S = (λ, τ), where λ is the particular value taken by vi during its associ-
ated interval τ = [a, b], corresponding to the time interval in which the state
changes, i.e. change in value occurs. In addition, each TN contains an extra
default state s = (‘Not’, ∅) with no associated interval. Time is discretized
in a finite number of intervals, allowing a different number and duration of
intervals for each node (multiple granularity). Each interval, defined for a
child node, represents the possible delays between the occurrence of one of
its parent events and the corresponding child event. If a node lacks defined
intervals for all its states then it is referred to as instantaneous node. There
is at most one state change for each variable (TN) in the temporal range of
interest.
Formally, let V be a set of temporal and instantaneous nodes and E a
set of arcs between nodes, a TNBN is defined as:
Definition 1. A TNBN is a pair B = (G,Θ) where G is a directed acyclic
graph, G = (V,E) and, Θ is a set of parameters quantifying the network.
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Figure 1: An example of a TNBN. Each oval represents a random variable. All the nodes
have prior probabilities associated with each state. The three upper nodes (collision,
head injury and internal bleeding) are instantaneous nodes, so they do not have tem-
poral intervals. The dilated pupils and vital signs are temporal nodes with intervals
associated with them.
Θ contains the values Θvi = P (vi|Pa(vi)) for each vi ∈ V; where Pa(vi)
represents the set of parents of vi in G.
The following is an example of a TNBN based on [25], its corresponding
graphical representation is shown in Figure 1. Each node in the TNBN has
a conditional probability table. For the sake of visualization, we decided
to present only the prior probabilities for each state of the node. They are
calculated with the learned parameters and then propagating probabilities
over the network.
Example 1. Assume that at time t = 0, an accident occurs, a collision.
This kind of accident can be classified as severe, moderate and mild. For
the sake of simplicity let us consider only two immediate consequences for
the person involved in the collision, head injury and internal bleeding. Head
Injury can take two values true or false, internal bleeding can be gross, slight
or false. These events will generate subsequent changes that are not imme-
diate: dilated pupils and unstable vital signs, that depend on the severity of
the accident. These events ( dilated pupils and vital signs) have temporal
intervals associated. Dilated pupils has three intervals {[0-15] [15-30] [30-
60]} and vital signs has two intervals {[0-10], [10-45]}. For this example,
the intervals represent minutes and a physician would appreciate not only
the information of the occurrence of the events but also the time at which
they appear, in order to obtain a better evaluation/diagnosis of the person.
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For instance, if a collision is severe, the person involved has high probability
of having a head injury and therefore to have dilated pupils in the first 15
minutes after the accident. On the other side, if a collision is mild, then
the probability of having a head injury is low, thus the probability of having
dilated pupils is extremely low.
As mentioned, there are several methods to learn BNs from data [17].
Unfortunately, none of the algorithms used to learn BNs deal with learn-
ing temporal intervals. Therefore, these cannot be applied directly to learn
TNBNs. The learning algorithm for TNBN used in this work has been pre-
sented in [27]. Briefly, the learning algorithm proceeds as follows:
1. First, it performs an initial discretization of the temporal variables,
for example using an equal-width discretization. With this process it
obtains an initial approximation of the intervals for all the Temporal
Nodes.
2. Then it performs a standard BN structural learning, the K2 learning
algorithm [28] is used to obtain an initial structure.
3. The interval learning algorithm refines the intervals for each TN by
means of clustering. For this, it uses the information of the configura-
tions of the parent nodes. To obtain some intervals a Gaussian mixture
model is used as a clustering algorithm for the temporal data. Each
cluster corresponds, in principle, to a temporal interval. The intervals
are defined in terms of the mean and the standard deviation of the clus-
ters. The algorithm obtains different sets of intervals that are merged
and combined, this process generates different interval sets that will be
evaluated in terms of the predictive accuracy (relative brier score). The
algorithm applies two pruning techniques in order to remove some sets
of intervals that may not be useful and also to keep a low complexity of
the TNBN. The best set of intervals (that may not be those obtained
in the first step) for each TN is selected based on predictive accuracy.
When a TN has as parents other temporal nodes (an example of this
situation is illustrated in Figure 4), the configurations of the parent
nodes are not initially known. In order to solve this problem, the in-
tervals are sequentially selected in a top-down fashion according to the
TNBN structure.
The algorithm then iterates between structure learning and interval learning.
However, for the experiments presented in this work, we show the results of
only one iteration.
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5. Finding pathways - a simple approach
This section presents a first experiment in which the objective is to com-
pare the TNBN model with different approaches. Therefore, we used a simple
approach for selecting the mutations and drugs to be included in the models.
We present the learned TNBN and compare it to, static Bayesian networks,
dynamic Bayesian networks and association rules.
5.1. Data and preprocessing
Clinical data from 2373 patients with HIV subtype B was retrieved from
the HIV Stanford database (HIVDB) [5, 6]. We chose to work with this sub-
type because it is the most common in the Americas [29], our geographical
region of interest. The isolates in the HIVDB were obtained from longitu-
dinal treatment profiles reporting the evolution of mutations in individual
sequences.
For each patient, data consisted of an initial treatment (a combination of
drugs) administered to the patient and a list of laboratory resistance tests
at different times (in weeks). Each test included a list of the most frequent
mutations in the viral population within the host at a specific time after the
initiation of treatment. An example of the data is presented in Table 1. The
number of studies available varied from 1 to 10 studies per patient history.
Since we are interested in temporal evolution of the mutational networks, we
filtered out those patients having only one study.
Table 1: An example of the data. Patient Pat1 with 3 temporal studies, and patient Pat2
with two temporal studies.
Patient Initial Treatment List of Mutations Time (Weeks)
Pat1 LPV, FPV, RTV
L63P, L10I 15
V77I 25
I62V 50
Pat2 NFV, RTV, SQV
L10I 25
V77I 45
In order to apply the TNBN learning algorithm, the data exemplified in
Table 1 was transformed into another table similar to the one presented in
Table 2, where each column represents a drug or mutation, and each row
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represents a patient case. For the drugs, the values were: used or not used,
and for the mutations the values were: appear with the number of weeks
elapsed before the mutation appeared for the first time or not, when the
mutation did not appear in that case.
Table 2: An example of the data used to learn the TNBN model. Each row represents a
patient. Each column represents whether a drug is used or not, or whether a mutation
appeared or not.
Drug-1 Drug-2 Drug-3 . . . Mutation-1 Mutation-2 . . .
LPV FPV NFV . . . L63P M36I . . .
Used Used Not Used . . . (Appear) 15 Not
Antiretrovirals are usually classified according to the enzyme that they
target. We focused on the viral protease, as this is the smallest of the vi-
ral enzymes in terms of number of aminoacids. Nine protease inhibitors
are currently available, namely: Amprenavir (APV), Atazanavir (ATV),
Darunavir (DRV), Lopinavir (LPV), Indinavir (IDV), Nelfinavir (NFV), Ri-
tonavir (RTV), Tripanavir (TPV) and Saquinavir (SQV). All 9 PIs were
considered during this experiment. Figure 2 presents a histogram of the fre-
quency of administration of each PI in the individuals included in the dataset.
Data retrieved belong to a period of 10 years, from 1995 to 2005. Since data
from HIVDB originates from different studies, it was not rare to find some
fields with missing data. Figure 2 evidences a small portion of cases report-
ing the administration of a PI, without describing the specific drug. Also,
there was a small proportion of cases reporting an unknown drug. To handle
this missing data, if the patient case only contained unknown or none in the
drug fields that case was removed. However, if the case contained other drug
(apart from unknown), that information was included in the model. After
removing the incomplete cases and the cases without temporal information
we ended up with a final set of 973 patients.
In order to define a target set of relevant mutations, we used a simple
frequency approach. Figure 3 shows a frequency histogram of mutations
appearing in the original dataset. A total of 733 different mutations appeared
at least once in the data; however, most of the mutations were rare. Thus, we
only considered mutations appearing more than 1500 times in the dataset:
L63P, I93L, V77I, I62V, L10I, E35D, L90M, M36I, A71V and R41K
(shown in black columns in Figure 3).
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Figure 2: Histogram of the protease inhibitors administration in the full dataset including
all 2373 patients.
The order of variables provided to the K2 algorithm was also determined
by frequency: first the antiretrovirals sorted by frequency, then the selected
mutations sorted by frequency.
5.2. Model evaluation and results
Since a gold standard or a reference TNBN does not exist, three indirect
measurements were used for the evaluation of the model: the relative Brier
score (RBS), the relative time error and the total number of intervals in the
model. For learning, 80% of the total 973 patients was used. The remaining
20% was used for evaluation.
The Brier score is a measure of the predictive accuracy of the network,
and it is defined as:
BS =
1
n
n∑
i=1
(1− Pi)2
where Pi is the marginal posterior probability of the correct value of each
node given the evidence, this applies for all the selected nodes, n, of the
TNBN. The RBS is defined as:
RBS (in %) = (1−BS)× 100
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Figure 3: A group of mutations and their frequency in the full dataset including all 2373
patients. The higher frequency end of the spectrum is zoomed. Mutations used for the
experiment are shown in black.
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For each case of the data (a row in Table 1), the RBS is obtained by in-
stantiating a random subset of variables in the model, predicting the unseen
variables, and obtaining the RBS for these predictions.
The relative temporal error (RTE) evaluates the temporal part of the
model. First, we define the expected time as:
te = (tend + tini)/2
where tini and tend are the initial and final values of the interval, so the
expected time is the average of them. The range of a temporal node T is the
difference between the maximum and the minimum value of all the intervals
in the node. The relative temporal error for a Temporal node T with respect
to the original value torig is defined as:
RTE =
|te − torig|
range(T )
this is the difference between the real event (original data) and the expected
mean of the interval, normalized by the range of T .
Finally, the number of intervals is defined as the total number of intervals
learned across all variables, this is a rough estimate of the complexity of the
network and a low number of intervals is a desirable property for simplicity
of the model.
The best model would afford a high RBS, a low time error and a low com-
plexity (low number of intervals). The technical performance of the model
reflects its predictive accuracy and complexity, but it should not be confused
with the biological/physiological plausibility of the model.
Since the learning algorithm finds a local maximum, and thus is influenced
by initial parametrization; for our experiments, the number of initial intervals
was allowed to vary from 2 to 4 and equal-width discretization [30] was used
to initialize those intervals.
Table 3 summarizes the results of the experiments and Figure 4 illus-
trates the best TNBN model instantiation in terms of higher RBS for the
experiment. The figure represents the network, the intervals and the prior
probabilities obtained for each TN.
Results show that for different initial intervals there is a small variation
in the three measures used. It is important to note that, all the models
obtained competitive predictive scores of nearly 90%.
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Table 3: Evaluation of the models in terms of RBS, RTE (in percentage), and number of
intervals. The best results are shown in boldface type.
Initial intervals RBS RTE Number of total intervals
2 87.3 15.0 30
3 88.5 14.7 31
4 87.5 15.9 35
Finding common structures
Statistical significance of edge strengths can be evaluated using bootstrap-
ping [23]. In non-parametric boostrapping, a re-shuﬄed dataset is generated
from the original (re-sampling with replacement), the graph is built from this
new dataset and the procedure is repeated a number of times. Confidence
in a particular edge is measured as a percentage of the number of times that
edge actually appears in the set of reconstructed graphs. We performed 20-
fold bootstrapping and used two thresholds for classifying the significance of
the observed relations. A strong relation was defined as that appearing at
least in 90% of the graphs, a suggestive relation was defined as that observed
between bootstrap values of 75% and 90%.
In Figure 5 we present the identified relations using bootstrapping. Re-
markably, in the set of the suggestive and strong relationships between muta-
tions, we observe five previously described highly correlated mutation pairs
[31]: (E35D, M36I), (L10I, L90M), (L10I, A71V), (V77I, I93L), and (L63P,
L90M). This is an important result that shows that our model is able to
capture important relations from data.
5.3. Clinical analysis of the model
Some clinical interpretations can be drawn from the associations obtained
by the model depicted in Figure 4. For example, the model revealed the
linking of RTV with IDV, NFV, ATV, APV and LPV. This relationship
of RTV with other drugs can be explained due to the fact that RTV is
widely used to boost the effect of other PIs, and therefore most of the times
it is administered in combination with other drugs. Another noteworthy
observation is that the DRV node in the model is isolated because in the
data, this drug was never given as part of a first treatment regimen for any
of the patients. This can be expected as DRV is a relatively new drug and
its use is mostly restricted to salvage regimens.
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Figure 4: A learned TNBN with 9 protease inhibitors and 10 high frequency mutations.
Drugs are indicated in white ovals and mutations in gray ovals. Learned time intervals
for the TNs are indicated beside the ovals. Thicker arrows represent highly correlated
mutations [31].
Interestingly, the local neighborhoods in the graph clearly revealed two
clusters of covarying mutations:
* L63P, I62V, L10I, L90M and A71V
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Figure 5: A learned TNBN with bootstrapping. The patterns that appeared ≥ 90% are
shown in a thick arrows, those that obtained ≥ 75% but < 90% are shown in thin arrows.
The letter C’ in the arrows represents highly correlated mutations [31].
* I93L, V77L, M36I, E35D and R41K
Highly significant associations between these groups of mutations have
been previously observed using different models [31]. This observation sug-
gests that our model can predict highly significant patterns of amino acid
covariation.
L63P, a polymorphic mutation also selected by PIs, is a highly frequent
mutation in the viruses included in the dataset (Figure 3). Our model sug-
gests that in most cases this mutation tends to appear early in time, and
that its probability to appear decreases over time. Alternatively, L63P could
represent a common polymorphism in the circulating viruses appearing in a
large proportion of viruses even before being exposed to PIs. Interestingly
however, the model was able to predict previously described covariation of
L63P with other PI-selected mutations such as L90M, L10I, A71V and I62V
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[31], suggesting the existence of drug-selected mutational pathways. This
property of the model could make it a powerful tool to detect not only drug-
associated codon covariation, but also immune-associated codon covariation.
The detection of mutational pathways associated with adaptation to fre-
quent immune responses in a given population would be relevant for vaccine
research and immunogen design.
5.4. Comparison with other methods
In this section, we compare and contrast the results obtained using the
TNBN model with three other approaches, namely: static Bayesian networks,
dynamic Bayesian networks and association rules.
Static Bayesian network
To establish whether the temporal model is providing additional infor-
mation we develop a comparison between a TNBN and a static Bayesian
network. In order to apply a static learning algorithm, we remove the tem-
poral information of the mutations. Hence, the states for both the drugs
and the mutations were: appear or not appear. We used the same ordering
as in the previous experiments and applied the K2 learning algorithm. The
static BN learned is presented in Figure 6.
From the model we can see that the number of arcs increased approxi-
mately in 66%. However in this model the nodes are binary, in contrast in the
TNBN model the nodes have more states that corresponds to the intervals.
We performed a comparison in terms of the number of values that contain
the conditional probability tables for these models. For the TNBN there are
432 values whereas in the static BN there are 276 values. Even when the
TNBN is not simpler in terms of parameters, the model can be intuitively
understood.
We computed the RBS for this static BN obtaining a value of 91.3 com-
pared to 87.3, 88.5 and 87.5 for the learned TNBNs. According to the Brier
score the static BN is slightly superior (about 3 points) to the TNBN, how-
ever we consider that this comparison is not strictly fair as the static BN
only predicts the state (appear / not appear) while the TNBN gives addi-
tional information, not only the state but also the temporal interval when it
changes.
We also performed a structural comparison. In this sense, a common mea-
sure of complexity in graph theory is density [32] defined as D = |E|
(2)|V ||V−1| ,
where |V | corresponds to the number of vertices and |E| to the number of
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Figure 6: A learned static BN with 9 protease inhibitors and 10 mutations that appear fre-
quently. Drugs are indicated in white ovals, their states are used or not used. Mutations
are shown in gray ovals, their states are appear or not appear. States and probabilities
are hidden for readability.
edges of the graph. The maximal density is 1 for complete graphs, when
the graph is fully connected and the minimal is 0 if all nodes are isolated.
This measure was computed for the TNBN in Figure 4 and the static BN.
The TNBN obtained D = 0.1578 and the BN obtained D = 0.2456. This
measure quantitatively summarizes that the TNBN model is sparser than
the respective BN, which in general implies that is easier to understand.
Dynamic Bayesian network
A dynamic Bayesian network extends the concept of a Bayesian network
to incorporate temporal information. Just as with static BNs, a probabilistic
18
Figure 7: A learned DBN using the same data. Persistence arcs are not shown. Thicker
arrows from nodes V77I and L63P directed to the dotted rectangle represent arrows from
V77I and L63P to each one of the nodes inside the rectangle.
model is created to represent a process at a single point in time. Multiple
copies of this model are then generated for each time point or slice belonging
to a temporal range of interest. Links between copies are inserted to capture
temporal relations.
The learning of a DBN can be seen as a two stage process. The first stage
refers to the learning of the static model and is done in an identical manner
as with classic BNs. The second stage learns the transition network, that is,
the temporal relations between random variables of different time slices.
For this experiment we learned a simple DBN using the Chow-Liu algo-
rithm [33] to generate the static network, and the Rebane and Pearl algorithm
[34] to learn the directions of the arcs. The transition network was learned
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using Kevin Murphy’s Bayesian network toolbox [35] using the Bayesian in-
formation criterion to select the best parents from the previous time slice.
Figure 7 shows the learned DBN as a 2-TBN. The learned DBN shows some
common relations with the TNBN; it also discovered the same well known
mutational correlations that the TNBN discovered (although not always in
the same direction). While the DBN successfully captured most of the rela-
tions shown in the TNBN, the DBN notoriously becomes more cluttered than
the TNBN, impairing its visual interpretation. We also note that the DBN
lacks the intuitive visual information to provide temporal orderings between
mutations.
Association rules
Finally, a different approach that is not related to BNs is presented. The
comparison uses association rules as the method to analyze the clinical in-
formation. In particular we used the apriori algorithm [36] with the same
data used in the previous experiment.
Different measures have been introduced to evaluate the quality of the
rules obtained by the algorithm, we used three common measures: confidence
[36], lift [37], and conviction [37]. In order to define these measures, first we
define the support of an itemset supp(X) as the proportion of instances which
contains that itemset, then:
• Confidence is defined as conf(X → Y ) = supp(X ∪ Y )/supp(Y ) and
can be interpreted as the probability of P (Y |X).
• Lift is defined as lift(X → Y ) = supp(X ∪ Y )/supp(Y )× supp(X), it
can be interpreted as the ratio of the observed support of both X and
Y (X ∪ Y ) divided by X and Y independently.
• Conviction is defined as conv(X → Y ) = 1− supp(Y )/1− conf(X− >
Y ) and can be interpreted as the ratio of the expected frequency that
X occurs without Y (the frequency of making an incorrect prediction).
In the upper part of Table 4 we present rules that obtained confidence over
0.9, in the lower part of the Table, we present some rules that are consistent
with the findings of our TNBN model with their respective results.
While association rules could obtain similar results to the TNBN model,
they have several drawbacks. The first one is the difficulty of incorporating
temporal information. One could think to separate each interval of the tem-
poral nodes into a different variable and apply the same Apriori algorithm.
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Table 4: On the upper part the rules that obtained confidence over 0.9 are presented. On
the lower part, several rules that are consistent with the results of our TNBN model.
Rule Confidence Lift Conviction
L10I=yes L90M=yes → L63P=yes 0.93 1.11 2.2
IDV=yes L90M=yes →L63P=yes 0.92 1.1 2
L90M=yes →L63P=yes 0.91 1.1 1.91
NFV=yes L90M=yes → L63P=yes 0.91 1.09 1.81
RTV=yes L90M=yes → L63P=yes 0.91 1.09 1.72
SQV=yes L90M=yes → L63P=yes 0.9 1.08 1.63
I62V=yes → L63P=yes 0.87 1.04 1.23
L63P=yes I93L=yes → IDV=yes 0.79 1.1 1.33
L63P=yes L10I=yes → L90M=yes 0.74 1.35 1.72
SQV=yes L63P=yes → L90M=yes 0.73 1.35 1.7
I93L=yes → IDV=yes L63P=yes 0.69 1.13 1.24
A71V=yes → L10I=yes 0.68 1.3 1.47
SQV=yes L63P=yes → L10I=yes 0.65 1.25 1.36
IDV=yes L63P=yes → L90M=yes 0.62 1.14 1.19
IDV=yes L63P=yes → L10I=yes 0.61 1.17 1.22
A71V=yes → L90M=yes 0.60 1.25 1.41
L10I=yes → A71V=yes 0.59 1.3 1.32
L90M=yes → A71V=yes 0.56 1.25 1.25
IDV=yes L63P=yes → I93L=yes 0.56 1.13 1.14
L63P=yes → L10I=yes 0.54 1.03 1.03
The problem with this approach is that the number of variables will incre-
ment and their frequency will decrement by means of the partition process.
Other problem with this approach is that it produces a large number of
small rules. The number of rules could increment exponentially. Therefore
analyzing the complete set of rules becomes extremely difficult. Finally, if we
could select a manageable subset of rules it will not provide a global analysis
of the results, they will be scattered pieces of information.
In contrast, the TNBN model presents a global and easy to understand
model that can provide useful temporal information.
6. Finding mutational pathways with clinical relevance
In order to asses the practical relevance of the TNBN model, a second
experiment was designed, using a specific set of drugs and drug resistance
mutations that were selected according to the real use of PIs in the clinical
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Figure 8: A learned TNBN model. An arc labeled with a * represents a strong relation.
An arc without a * represents a suggestive relation.
setting. This experiment is presented in the following section.
6.1. Data
To test the ability of the model to predict clinically relevant data, a subset
of patients from the original dataset was selected, including individuals that
received ART regimes including LPV, IDV, and SQV. Relevant major drug
resistance mutations associated with the selected drugs were included [36].
The mutations selected were: V32I, M46I, M46L, I47V, G48V, I54V, V82A,
I84V, and L90M. Since we used a subset of drugs, the number of patients in
the final dataset was reduced from the previous experiments to 300 patients.
6.2. Evaluation of the model and results
In order to evaluate the models and to measure the statistical significance
of edge strengths we used non-parametric bootstrapping. Two thresholds
were defined for considering a relation as important. A strong relation was
defined as one that appeared at least in 90% of the graphs, and a suggestive
relation was defined as one that occurred with values between 70% and 90%.
In Figure 8 a suggestive relation is shown as an arrow, and a strong relation
is presented as an arrow labeled with an asterisk (*).
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Since the approach for selecting the drugs and mutations is based on
experts opinion, we used a more elaborate way to obtain the order for the
K2 algorithm. For this experiment we evaluated different orderings for the
K2 algorithm. Specifically, we evaluated all the
(
9
2
)
different combinations for
the first two mutations, since they are important and the order of the rest was
chosen randomly. We evaluated the models with respect to their accuracy
and in Figure 8 the model with highest predictive accuracy is presented.
6.3. Clinical relevance
The model was able to predict clinically relevant associations between
the chosen drugs and mutations. Indeed, a strong association between SQV,
G48V, and I84V was readily predicted in the model, although no temporal as-
sociations were observed between the two mutations. All three drugs showed
direct associations with L90M reflecting the fact that this mutation causes
cross-resistance to many members of the PI family. Remarkably, the two
possible mutational pathways for LPV resistance [38–40]. were predicted:
• I54V → V32I → I47V
• L90M → M46IL → I84V
Whether the temporal order of mutations is relevant, still needs to be
further evaluated. Also, the shared mutational pathway between IDV and
LPV was observed, involving mutations L90M, M46IL, I54V, V82A and I84V.
7. Conclusions
Mutational pathways provide important information for decision making
in multi-drug therapy. By using temporal nodes Bayesian networks we have
been able to unveil common mutational pathways present in HIV evolution as
response to pharmacological selective pressure. Our model was successful in
capturing relationships between mutations and protease inhibitors critically
incorporating temporal information. These results are encouraging, present-
ing the model as an interesting tool to explain how mutations interact with
each other, providing information not only in association patterns, but also
in the temporal order of appearance of mutations selected by antiretroviral
drugs. With a carefully selected dataset, the model could be also useful
to predict timeframes between the appearance of different mutations. This
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could lead to recommendations in the timing of resistance testing and ther-
apy changes in order to avoid the further loss of possible treatment options
for patients with exposure to multiple antiretroviral regimens.
The main contribution of this paper is to use a temporal probabilistic
approach to understand HIV mutations. The models were developed using
only data, however, some important known correlated mutations were dis-
covered, as well as other temporal relations. We also compared the TNBN
approach with other models such as Bayesian networks and association rules.
Even that the compared models obtained important information they were
not capable of providing a global and complete model showing the temporal
process of the problem.
It would be interesting to test TNBN with data involving complete an-
tiretroviral regimens. This could be useful in retrospectively comparing the
effectiveness of different regimes, predicting the patterns of mutations most
frequently selected by similar regimens and the timing of appearance of these
mutations in specific settings. The evaluation of resistance patterns in differ-
ent settings (providing larger datasets available) would be relevant as social
factors such as: patient adherence to treatment, availability of drugs, as well
as genetic factors that could alter pharmacodynamics in specific populations,
could be considered in the model.
The relevance of TNBN could be further extended to the vaccine field. It
is well known that there is remarkable coevolution of positions in the viral
genome, which depends on host genetic factors defining specific immune re-
sponses against the virus. These genetic factors, namely the human leukocyte
antigen genes are highly polymorphic, with highly variable allelic frequency
distributions in different populations. The possibility of discovering these
coevolution patterns in the context of different populations, as well as the
timing of appearance of different variants in the coevolving codons could be
a very useful tool in predicting immunogen responses and designing putative
vaccines.
Future work plans are to compare two different cocktail treatments along
with the temporal occurrence of drug resistant mutations, in order to predict
the most effective treatment. We believe this could aid the experts in the
selection of the best treatment for the patient.
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